Physician profile
Daniel E Harvey
NPI 1194759688
$10,911.52
in general payments reported to CMS, 2019-2025
43 companies · $172 in 2025
The $172 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,261 · 2020: $1,588 · 2021: $2,518 · 2022: $1,550 · 2023: $1,252 · 2024: $1,571 · 2025: $172.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,986 · Education: $8.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,986.27 |
| Education | $8.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $2,859.25 | 2019-2024 | Xarelto |
| Abbvie INC. | $1,265.91 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $986.49 | 2019-2024 | Breztri, Farxiga, Airsupra |
| Merck Sharp & Dohme LLC | $798.26 | 2019-2024 | Verquvo, Belsomra, Steglatro |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $610.00 | 2019-2024 | Xifaxan |
| Amarin Pharma, INC. | $506.28 | 2019 | |
| Lilly USA, LLC | $473.48 | 2020-2024 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $292.91 | 2019-2023 | Otezla, Repatha |
| Vanda Pharmaceuticals INC. | $274.00 | 2020-2022 | |
| Astellas Pharma US INC | $273.94 | 2019-2024 | Veozah |
| Allergan, INC. | $259.76 | 2019-2020 | |
| Novo Nordisk INC | $243.80 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Sunovion Pharmaceuticals INC. | $229.45 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $226.94 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $192.19 | 2019-2024 | Jardiance |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Harvey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.